BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golla K, Cherukuvada B, Ahmed F, Kondapi AK. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One. 2012;7:e51960. [PMID: 23284832 DOI: 10.1371/journal.pone.0051960] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Aljabali AA, Rezigue M, Alsharedeh RH, Obeid MA, Mishra V, Serrano-Aroca Á, El-Tanani M, Tambuwala MM. Protein-based nanomaterials: a new tool for targeted drug delivery. Ther Deliv 2022. [PMID: 35924586 DOI: 10.4155/tde-2021-0091] [Reference Citation Analysis]
2 Malone CD, Egbulefu C, Zheleznyak A, Polina J, Karmakar P, Black K, Shokeen M, Achilefu S. Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma. Sci Rep 2022;12:12748. [PMID: 35882949 DOI: 10.1038/s41598-022-17185-0] [Reference Citation Analysis]
3 Bukhari S, Siddique MH, Naeem A, Khan I, Ali Z, Essa A, Fazal F, Anis RA, Moran L, Sultan A, Murtaza I, Vanhara P, Anees M. Combined efficacy of Cinnamomum zeylanicum and doxorubicin against leukemia through regulation of TRAIL and NF-kappa B pathways in rat model. Mol Biol Rep 2022. [PMID: 35579734 DOI: 10.1007/s11033-022-07478-y] [Reference Citation Analysis]
4 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sunnam LBK, Kondapi AK. Topoisomerase II β Gene Specific siRNA Delivery by Nanoparticles Prepared with c-ter Apotransferrin and its Effect on HIV-1 Replication. Mol Biotechnol 2021;63:732-45. [PMID: 33993458 DOI: 10.1007/s12033-021-00334-7] [Reference Citation Analysis]
6 Moraes S, Marinho A, Lima S, Granja A, Araújo JP, Reis S, Sousa CT, Nunes C. Targeted nanostructured lipid carriers for doxorubicin oral delivery. Int J Pharm 2021;592:120029. [PMID: 33130218 DOI: 10.1016/j.ijpharm.2020.120029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kumar V, Rahman M, Gahtori P, Al-Abbasi F, Anwar F, Kim HS. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Deliv 2021;18:673-94. [PMID: 33295218 DOI: 10.1080/17425247.2021.1860939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Lee S, Kim JH, Moon H, Lee HJ, Han JK. Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study. PLoS One 2020;15:e0243815. [PMID: 33306731 DOI: 10.1371/journal.pone.0243815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Elzoghby AO, Abdelmoneem MA, Hassanin IA, Abd Elwakil MM, Elnaggar MA, Mokhtar S, Fang JY, Elkhodairy KA. Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand. Biomaterials 2020;263:120355. [PMID: 32932142 DOI: 10.1016/j.biomaterials.2020.120355] [Cited by in Crossref: 16] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
10 Abdelmoneem MA, Abd Elwakil MM, Khattab SN, Helmy MW, Bekhit AA, Abdulkader MA, Zaky A, Teleb M, Elkhodairy KA, Albericio F, Elzoghby AO. Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-κB inhibitor celastrol. Mater Sci Eng C Mater Biol Appl 2021;118:111422. [PMID: 33255023 DOI: 10.1016/j.msec.2020.111422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
11 Kondapi AK. Targeting cancer with lactoferrin nanoparticles: recent advances. Nanomedicine (Lond) 2020;15:2071-83. [PMID: 32779524 DOI: 10.2217/nnm-2020-0090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
12 Sabra S, Agwa MM. Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications. Int J Biol Macromol 2020;164:1046-60. [PMID: 32707283 DOI: 10.1016/j.ijbiomac.2020.07.167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
13 Bhavsar DB, Patel V, Sawant KK. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy. Eur J Pharm Sci 2020;152:105428. [PMID: 32553643 DOI: 10.1016/j.ejps.2020.105428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Abdelmoneem MA, Elnaggar MA, Hammady RS, Kamel SM, Helmy MW, Abdulkader MA, Zaky A, Fang J, Elkhodairy KA, Elzoghby AO. Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2019;11:26731-44. [DOI: 10.1021/acsami.9b10164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
15 Kumari S, Bhattacharya D, Rangaraj N, Chakarvarty S, Kondapi AK, Rao NM. Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma. Nanomedicine 2018;13:2579-96. [DOI: 10.2217/nnm-2018-0110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
16 Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang J, Elkhodairy KA, Elzoghby AO. Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma. Nanomedicine 2018;13:2377-95. [DOI: 10.2217/nnm-2018-0134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
17 Madugulla L, Ravula AR, Kondapi AK, Yenugu S. Evaluation of the reproductive toxicity of antiretroviral drug loaded lactoferrin nanoparticles. Syst Biol Reprod Med 2019;65:205-13. [PMID: 30260720 DOI: 10.1080/19396368.2018.1519047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ahmed F, Kumari S, Kondapi AK. Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2457-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
19 Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A, Pontisso P. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. J Control Release 2017;268:184-97. [PMID: 29051062 DOI: 10.1016/j.jconrel.2017.10.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
20 Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep 2017;7:6602. [PMID: 28747713 DOI: 10.1038/s41598-017-06888-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 70] [Article Influence: 11.2] [Reference Citation Analysis]
21 Adimoolam MG, A. V, Nalam MR, Sunkara MV. Chlorin e6 loaded lactoferrin nanoparticles for enhanced photodynamic therapy. J Mater Chem B 2017;5:9189-96. [DOI: 10.1039/c7tb02599h] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
22 Kumar P, Lakshmi YS, Kondapi AK. Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy. Pharm Res 2017;34:257-68. [PMID: 27928647 DOI: 10.1007/s11095-016-2048-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
23 Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine 2016;11:5645-69. [PMID: 27920520 DOI: 10.2147/IJN.S115727] [Cited by in Crossref: 67] [Cited by in F6Publishing: 81] [Article Influence: 11.2] [Reference Citation Analysis]
24 Rao PS, Midde NM, Miller DD, Chauhan S, Kumar A, Kumar S. Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1. Curr Drug Metab 2015;16:486-503. [PMID: 26264202 DOI: 10.2174/1389200216666150812123554] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
25 Lakshmi YS, Kumar P, Kishore G, Bhaskar C, Kondapi AK. Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles. Sci Rep 2016;6:25479. [PMID: 27151598 DOI: 10.1038/srep25479] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
26 Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12022-12041 [PMID: 26576089 DOI: 10.3748/wjg.v21.i42.12022] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
27 Kumar P, Lakshmi YS, C B, Golla K, Kondapi AK. Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats. PLoS One 2015;10:e0140399. [PMID: 26461917 DOI: 10.1371/journal.pone.0140399] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
28 Fedotcheva TA, Olenin AY, Starostin KM, Lisichkin GV, Banin VV, Shimanovskii NL. Prospects for Using Gold, Silver, and Iron Oxide Nanoparticles for Increasing the Efficacy of Chemotherapy. Pharm Chem J 2015;49:220-30. [DOI: 10.1007/s11094-015-1260-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
29 Taguchi K, Yamasaki K, Seo H, Otagiri M. Potential Use of Biological Proteins for Liver Failure Therapy. Pharmaceutics 2015;7:255-74. [PMID: 26404356 DOI: 10.3390/pharmaceutics7030255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhang YJ, Zhan X, Wang L, Ho RJ, Sasaki T. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci 2015;104:1815-24. [PMID: 25753991 DOI: 10.1002/jps.24407] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
31 Wang H, Thorling CA, Liang X, Bridle KR, Grice JE, Zhu Y, Crawford DHG, Xu ZP, Liu X, Roberts MS. Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. J Mater Chem B 2015;3:939-58. [PMID: 32261972 DOI: 10.1039/c4tb01611d] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
32 Yan JJ, Liao JZ, Lin JS, He XX. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems. Tumour Biol. 2015;36:55-67. [PMID: 25424700 DOI: 10.1007/s13277-014-2855-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
33 Chastagner P, Sudour H, Mriouah J, Barberi-heyob M, Bernier-chastagner V, Pinel S. Preclinical Studies of Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-Grade Glioma Xenografts. Pharm Res 2015;32:158-66. [DOI: 10.1007/s11095-014-1452-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
34 Saneja A, Khare V, Alam N, Dubey RD, Gupta PN. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opinion on Drug Delivery 2013;11:121-38. [DOI: 10.1517/17425247.2014.865014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
35 Golla K, Bhaskar C, Ahmed F, Kondapi AK. A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J Cancer 2013;4:644-52. [PMID: 24155776 DOI: 10.7150/jca.7093] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
36 Mishra D, Hubenak JR, Mathur AB. Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy: Nanoparticles for Drug Delivery. J Biomed Mater Res 2013;101:3646-60. [DOI: 10.1002/jbm.a.34642] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]